Go Pro
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel Free BBNX Stock Alerts

Beta Bionics (BBNX) Financials

Beta Bionics logo
$15.67 -1.33 (-7.82%)
Closing price 06/30/2026 04:00 PM Eastern
Extended Trading
$15.76 +0.10 (+0.61%)
As of 08:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Beta Bionics

Annual Income Statements for Beta Bionics

This table shows Beta Bionics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -44 -55 -73
Consolidated Net Income / (Loss)		 -44 -55 -73
Net Income / (Loss) Continuing Operations		 -44 -55 -73
Total Pre-Tax Income 		-44 -55 -73
Total Operating Income		 -36 -45 -72
Total Gross Profit		 6.31 36 56
Total Revenue		 12 65 100
Operating Revenue		 12 65 100
Total Cost of Revenue		 5.69 29 45
Operating Cost of Revenue		 5.69 29 45
Total Operating Expenses		 42 81 127
Selling, General & Admin Expense		 12 18 31
Marketing Expense		 12 37 61
Research & Development Expense		 18 26 35
Total Other Income / (Expense), net		 -8.25 -9.50 -1.52
Interest & Investment Income		 1.78 3.91 11
Other Income / (Expense), net		 -10 -13 -12
Basic Earnings per Share		 ($8.31) ($8.60) ($1.81)
Weighted Average Basic Shares Outstanding		 5.30M 6.37M 40.53M
Diluted Earnings per Share		 ($8.31) ($8.60) ($1.81)
Weighted Average Diluted Shares Outstanding		 5.30M 6.37M 40.53M
Weighted Average Basic & Diluted Shares Outstanding		 - 43.35M 44.38M

Quarterly Income Statements for Beta Bionics

This table shows Beta Bionics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -12 -14 -9.74 -18 -29 -17 -14 -13 -22
Consolidated Net Income / (Loss)		 -12 -14 -9.74 -18 -29 -17 -14 -13 -22
Net Income / (Loss) Continuing Operations		 -12 -14 -9.74 -18 -29 -17 -14 -13 -22
Total Pre-Tax Income 		-12 -14 -9.74 -18 -29 -17 -14 -13 -22
Total Operating Income		 -9.45 -12 -11 -13 -19 -20 -17 -16 -24
Total Gross Profit		 7.20 8.08 8.91 12 8.97 13 15 19 16
Total Revenue		 13 15 17 20 18 23 27 32 28
Operating Revenue		 13 15 17 20 18 23 27 32 28
Total Cost of Revenue		 5.73 6.96 7.79 8.75 8.67 11 12 13 11
Operating Cost of Revenue		 5.73 6.96 7.79 8.75 8.67 11 12 13 11
Total Operating Expenses		 17 20 20 25 28 32 32 35 41
Selling, General & Admin Expense		 3.51 4.54 5.11 4.71 6.62 7.88 7.92 8.60 9.62
Marketing Expense		 7.66 8.97 9.65 11 13 16 16 16 21
Research & Development Expense		 5.48 6.35 5.14 9.21 7.59 8.87 8.20 10 10
Total Other Income / (Expense), net		 -3.00 -2.68 1.24 -5.07 -10 3.00 2.83 2.66 2.38
Interest & Investment Income		 1.14 0.99 0.83 0.95 2.44 3.01 2.83 2.66 2.38
Other Income / (Expense), net		 -4.14 -3.67 0.42 -6.02 -12 -0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($2.07) ($2.37) ($1.46) ($2.70) ($0.93) ($0.39) ($0.33) ($0.16) ($0.49)
Weighted Average Basic Shares Outstanding		 6.02M 6.11M 6.66M 6.37M 30.71M 43.39M 43.63M 40.53M 44.44M
Diluted Earnings per Share		 ($2.07) ($2.37) ($1.46) ($2.70) ($0.93) ($0.39) ($0.33) ($0.16) ($0.49)
Weighted Average Diluted Shares Outstanding		 6.02M 6.11M 6.66M 6.37M 30.71M 43.39M 43.63M 40.53M 44.44M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 43.35M 43.36M 43.47M 44.02M 44.38M 44.56M

Annual Cash Flow Statements for Beta Bionics

This table details how cash moves in and out of Beta Bionics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -1.11 3.87 1.14
Net Cash From Operating Activities		 -32 -48 -51
Net Cash From Continuing Operating Activities		 -32 -48 -51
Net Income / (Loss) Continuing Operations		 -44 -55 -73
Consolidated Net Income / (Loss)		 -44 -55 -73
Depreciation Expense		 1.23 1.15 1.57
Amortization Expense		 0.87 1.13 1.37
Non-Cash Adjustments To Reconcile Net Income		 13 16 28
Changes in Operating Assets and Liabilities, net		 -3.22 -12 -8.99
Net Cash From Investing Activities		 -70 -3.48 -163
Net Cash From Continuing Investing Activities		 -70 -3.48 -163
Purchase of Property, Plant & Equipment		 -0.40 -3.40 -5.30
Purchase of Investments		 -69 -72 -328
Sale of Property, Plant & Equipment		 0.00 0.05 0.00
Sale and/or Maturity of Investments		 0.00 72 170
Net Cash From Financing Activities		 101 56 215
Net Cash From Continuing Financing Activities		 101 56 215
Repurchase of Common Equity		 0.00 -4.15 0.00
Issuance of Preferred Equity		 101 60 0.00
Issuance of Common Equity		 - 0.00 210
Other Financing Activities, net		 0.03 0.10 4.76

Quarterly Cash Flow Statements for Beta Bionics

This table details how cash moves in and out of Beta Bionics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -4.49 -9.04 4.45 13 12 -7.38 3.41 -6.91 -1.37
Net Cash From Operating Activities		 -12 -12 -9.61 -14 -20 -14 -8.73 -8.63 -24
Net Cash From Continuing Operating Activities		 -12 -12 -9.61 -14 -20 -14 -8.73 -8.63 -24
Net Income / (Loss) Continuing Operations		 -12 -14 -9.74 -18 -29 -17 -14 -13 -22
Consolidated Net Income / (Loss)		 -12 -14 -9.74 -18 -29 -17 -14 -13 -22
Depreciation Expense		 0.29 0.30 0.33 0.23 0.30 0.35 0.39 0.54 0.59
Amortization Expense		 0.28 0.28 0.28 0.30 -0.62 0.31 0.30 0.46 0.49
Non-Cash Adjustments To Reconcile Net Income		 4.62 4.34 1.21 6.18 15 4.12 4.48 5.18 5.41
Changes in Operating Assets and Liabilities, net		 -4.88 -2.69 -1.71 -2.88 -6.47 -1.50 0.32 -1.34 -8.21
Net Cash From Investing Activities		 7.64 3.30 15 -30 -179 6.17 9.49 0.66 22
Net Cash From Continuing Investing Activities		 7.64 3.30 15 -30 -179 6.17 9.49 0.66 22
Purchase of Property, Plant & Equipment		 -0.41 -0.51 -1.92 -0.56 -0.33 -1.78 -1.28 -1.90 -1.38
Purchase of Investments		 0.00 -20 -6.84 -45 -207 -15 -60 -45 -25
Sale of Property, Plant & Equipment		 0.05 - - - 0.00 - - - 0.00
Sale and/or Maturity of Investments		 8.00 24 24 16 28 23 71 48 48
Net Cash From Financing Activities		 0.01 -0.11 -1.18 57 211 0.04 2.65 1.06 0.62
Net Cash From Continuing Financing Activities		 0.01 -0.11 -1.18 57 211 0.04 2.65 1.06 0.62
Repayment of Debt		 - - -1.22 - 0.00 - - - 0.00
Issuance of Common Equity		 0.00 - - - 211 - - -0.90 0.00
Other Financing Activities, net		 0.01 0.01 0.05 0.04 0.10 0.04 2.65 1.96 0.62

Annual Balance Sheets for Beta Bionics

This table presents Beta Bionics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets		 110 150 329
Total Current Assets		 104 133 268
Cash & Equivalents		 27 30 32
Restricted Cash		 - 0.00 0.10
Short-Term Investments		 70 73 188
Accounts Receivable		 4.45 12 17
Inventories, net		 1.25 13 22
Prepaid Expenses		 1.18 4.03 9.84
Plant, Property, & Equipment, net		 2.48 4.78 8.60
Total Noncurrent Assets		 3.94 12 52
Long-Term Investments		 - 0.00 45
Other Noncurrent Operating Assets		 3.94 12 6.81
Total Liabilities & Shareholders' Equity		 110 150 329
Total Liabilities		 51 74 41
Total Current Liabilities		 11 21 31
Accounts Payable		 1.17 2.85 5.00
Accrued Expenses		 8.13 16 22
Current Deferred Revenue		 0.09 0.94 1.56
Other Current Liabilities		 1.22 1.53 1.94
Total Noncurrent Liabilities		 41 52 10
Capital Lease Obligations		 3.00 5.73 5.37
Noncurrent Deferred Revenue		 0.26 1.86 3.30
Other Noncurrent Operating Liabilities		 38 45 1.55
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -203 -245 288
Total Preferred & Common Equity		 -203 -245 288
Total Common Equity		 -203 -245 288
Common Stock		 26 51 657
Retained Earnings		 -230 -297 -370
Accumulated Other Comprehensive Income / (Loss)		 0.14 0.07 0.40

Quarterly Balance Sheets for Beta Bionics

This table presents Beta Bionics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 338 330 330 304
Total Current Assets		 262 286 270 248
Cash & Equivalents		 42 35 38 30
Restricted Cash		 - - - 0.10
Short-Term Investments		 189 215 190 169
Accounts Receivable		 9.06 11 12 16
Inventories, net		 16 17 20 24
Prepaid Expenses		 5.65 7.64 9.43 8.89
Plant, Property, & Equipment, net		 5.52 6.47 7.39 10
Total Noncurrent Assets		 71 37 53 46
Long-Term Investments		 64 31 45 40
Other Noncurrent Operating Assets		 6.59 6.28 7.31 6.41
Total Liabilities & Shareholders' Equity		 338 330 330 304
Total Liabilities		 24 28 35 33
Total Current Liabilities		 16 19 25 23
Accounts Payable		 3.45 3.42 4.46 2.32
Accrued Expenses		 11 13 18 17
Current Deferred Revenue		 0.95 1.14 1.34 1.71
Other Current Liabilities		 1.52 1.52 1.98 1.84
Total Noncurrent Liabilities		 7.78 8.85 9.90 9.98
Capital Lease Obligations		 5.45 5.17 5.71 5.07
Noncurrent Deferred Revenue		 2.33 2.67 2.99 3.35
Other Noncurrent Operating Liabilities		 0.00 1.01 1.21 1.56
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 314 302 295 271
Total Preferred & Common Equity		 314 302 295 271
Total Common Equity		 314 302 295 271
Common Stock		 639 644 651 663
Retained Earnings		 -325 -342 -356 -392
Accumulated Other Comprehensive Income / (Loss)		 0.24 0.15 0.35 -0.10

Annual Metrics And Ratios for Beta Bionics

This table displays calculated financial ratios and metrics derived from Beta Bionics' official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - 44,024,631.00
DEI Adjusted Shares Outstanding		 - - 44,024,631.00
DEI Earnings Per Adjusted Shares Outstanding		 - - -1.66
Growth Metrics		 - - -
Revenue Growth		 0.00% 442.93% 53.94%
EBITDA Growth		 0.00% -28.77% -44.01%
EBIT Growth		 0.00% -27.88% -43.41%
NOPAT Growth		 0.00% -26.22% -58.41%
Net Income Growth		 0.00% -24.17% -33.68%
EPS Growth		 0.00% -3.49% 78.95%
Operating Cash Flow Growth		 0.00% -48.78% -5.49%
Free Cash Flow Firm Growth		 0.00% 0.00% -123.07%
Invested Capital Growth		 0.00% 37.86% 229.69%
Revenue Q/Q Growth		 0.00% 0.00% 13.19%
EBITDA Q/Q Growth		 0.00% 0.00% 4.02%
EBIT Q/Q Growth		 0.00% 0.00% 3.37%
NOPAT Q/Q Growth		 0.00% 0.00% -4.50%
Net Income Q/Q Growth		 0.00% 0.00% 5.96%
EPS Q/Q Growth		 0.00% 0.00% 58.39%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 9.99%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 7.06%
Profitability Metrics		 - - -
Gross Margin		 52.59% 55.11% 55.40%
EBITDA Margin		 -365.03% -86.58% -80.99%
Operating Margin		 -298.87% -69.48% -71.50%
EBIT Margin		 -382.46% -90.08% -83.92%
Profit (Net Income) Margin		 -367.64% -84.08% -73.02%
Tax Burden Percent		 100.00% 100.00% 100.00%
Interest Burden Percent		 96.13% 93.34% 87.01%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -1,547.95%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -1,535.05%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 1,507.69%
Return on Equity (ROE)		 -75.24% -81.35% -40.26%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -354.29%
Operating Return on Assets (OROA)		 -41.69% -45.18% -35.17%
Return on Assets (ROA)		 -40.08% -42.17% -30.60%
Return on Common Equity (ROCE)		 260.76% 271.00% -4.68%
Return on Equity Simple (ROE_SIMPLE)		 21.71% 22.32% 0.00%
Net Operating Profit after Tax (NOPAT)		 -25 -32 -50
NOPAT Margin		 -209.21% -48.64% -50.05%
Net Nonoperating Expense Percent (NNEP)		 -20.27% -24.09% -12.89%
Return On Investment Capital (ROIC_SIMPLE)		 12.54% 13.22% -17.13%
Cost of Revenue to Revenue		 47.41% 44.89% 44.60%
SG&A Expenses to Revenue		 101.92% 27.44% 30.95%
R&D to Revenue		 149.59% 40.21% 34.70%
Operating Expenses to Revenue		 351.46% 124.59% 126.90%
Earnings before Interest and Taxes (EBIT)		 -46 -59 -84
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -44 -56 -81
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.00 0.00 4.29
Price to Tangible Book Value (P/TBV)		 0.00 0.00 4.29
Price to Revenue (P/Rev)		 17.01 3.13 12.32
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 34.45
Enterprise Value to Revenue (EV/Rev)		 31.01 6.56 9.73
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.05 0.08 0.02
Long-Term Debt to Equity		 0.05 0.08 0.02
Financial Leverage		 -1.60 -1.42 -0.98
Leverage Ratio		 1.88 1.93 1.32
Compound Leverage Factor		 1.80 1.80 1.14
Debt to Total Capital		 4.87% 7.01% 1.83%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 4.87% 7.01% 1.83%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 424.81% 393.17% 0.00%
Common Equity to Total Capital		 -329.68% -300.17% 98.17%
Debt to EBITDA		 -0.07 -0.10 -0.07
Net Debt to EBITDA		 2.14 1.74 3.19
Long-Term Debt to EBITDA		 -0.07 -0.10 -0.07
Debt to NOPAT		 -0.12 -0.18 -0.11
Net Debt to NOPAT		 3.74 3.09 5.17
Long-Term Debt to NOPAT		 -0.12 -0.18 -0.11
Altman Z-Score		 -0.79 -1.08 16.76
Noncontrolling Interest Sharing Ratio		 446.55% 433.13% 88.38%
Liquidity Ratios		 - - -
Current Ratio		 9.77 6.29 8.66
Quick Ratio		 9.54 5.46 7.64
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -45 -100
Operating Cash Flow to CapEx		 -8,152.01% -1,443.14% -961.39%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.11 0.50 0.42
Accounts Receivable Turnover		 2.70 7.92 6.89
Inventory Turnover		 4.57 4.01 2.55
Fixed Asset Turnover		 4.84 17.96 14.99
Accounts Payable Turnover		 4.88 14.55 11.39
Days Sales Outstanding (DSO)		 135.35 46.08 53.00
Days Inventory Outstanding (DIO)		 79.91 90.92 143.02
Days Payable Outstanding (DPO)		 74.84 25.08 32.04
Cash Conversion Cycle (CCC)		 140.42 111.92 163.98
Capital & Investment Metrics		 - - -
Invested Capital		 -35 -22 28
Invested Capital Turnover		 -0.34 -2.29 30.93
Increase / (Decrease) in Invested Capital		 0.00 13 50
Enterprise Value (EV)		 372 428 976
Market Capitalization		 204 204 1,235
Book Value per Share		 ($38.30) ($38.55) $6.53
Tangible Book Value per Share		 ($38.30) ($38.55) $6.53
Total Capital		 62 82 293
Total Debt		 3.00 5.73 5.37
Total Long-Term Debt		 3.00 5.73 5.37
Net Debt		 -94 -98 -259
Capital Expenditures (CapEx)		 0.40 3.35 5.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.73 8.20 18
Debt-free Net Working Capital (DFNWC)		 93 112 237
Net Working Capital (NWC)		 93 112 237
Net Nonoperating Expense (NNE)		 19 23 23
Net Nonoperating Obligations (NNO)		 -94 -98 -259
Total Depreciation and Amortization (D&A)		 2.09 2.28 2.94
Debt-free, Cash-free Net Working Capital to Revenue		 -31.09% 12.59% 17.71%
Debt-free Net Working Capital to Revenue		 775.46% 171.63% 236.39%
Net Working Capital to Revenue		 775.46% 171.63% 236.39%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 ($8.60) ($1.81)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 6.37M 40.53M
Adjusted Diluted Earnings per Share		 $0.00 ($8.60) ($1.81)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 6.37M 40.53M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 43.35M 44.38M
Normalized Net Operating Profit after Tax (NOPAT)		 -25 -32 -50
Normalized NOPAT Margin		 -209.21% -48.64% -50.05%
Pre Tax Income Margin		 -367.64% -84.08% -73.02%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -7.57% 0.00%

Quarterly Metrics And Ratios for Beta Bionics

This table displays calculated financial ratios and metrics derived from Beta Bionics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - 0.00 - - - 44,024,631.00 44,382,146.00
DEI Adjusted Shares Outstanding		 - - - 0.00 - - - 44,024,631.00 44,382,146.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - 0.00 - - - -0.31 -0.49
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 36.39% 54.45% 63.14% 57.15% 56.62%
EBITDA Growth		 0.00% 0.00% 0.00% 0.00% -134.07% -29.17% -64.46% 18.37% 26.13%
EBIT Growth		 0.00% 0.00% 0.00% 0.00% -128.82% -28.58% -61.35% 15.40% 21.94%
NOPAT Growth		 0.00% 0.00% 0.00% 0.00% -97.21% -68.64% -55.26% -23.68% -30.20%
Net Income Growth		 0.00% 0.00% 0.00% 0.00% -130.19% -16.64% -45.94% 25.64% 23.59%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 55.07% 83.54% 77.40% 94.07% 47.31%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% -64.48% -11.09% 9.20% 39.58% -19.31%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 18.16%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 229.69% 55.25%
Revenue Q/Q Growth		 0.00% 16.34% 11.03% 22.36% 0.00% 31.74% 17.28% 17.86% -13.99%
EBITDA Q/Q Growth		 0.00% -14.24% 33.15% -86.27% 0.00% 36.96% 14.89% 7.54% -53.38%
EBIT Q/Q Growth		 0.00% -13.75% 31.66% -80.43% 0.00% 36.08% 14.25% 5.39% -50.54%
NOPAT Q/Q Growth		 0.00% -24.66% 6.85% -18.77% 0.00% -6.60% 14.24% 5.39% -50.53%
Net Income Q/Q Growth		 0.00% -16.18% 32.68% -85.99% 0.00% 41.13% 15.77% 5.23% -62.59%
EPS Q/Q Growth		 0.00% -14.49% 38.40% -84.93% 0.00% 58.06% 15.38% 51.52% -206.25%
Operating Cash Flow Q/Q Growth		 0.00% -0.77% 21.44% -48.54% 0.00% 31.94% 35.79% 1.17% -176.25%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -8.34% 3.67% -60.08% 51.01%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 9.30% 2.01% 7.06% 30.06%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 55.68% 53.73% 53.36% 57.19% 50.86% 53.80% 55.48% 58.98% 59.50%
EBITDA Margin		 -100.71% -98.90% -59.55% -90.65% -172.84% -82.71% -60.03% -47.09% -83.97%
Operating Margin		 -73.09% -78.32% -65.71% -63.78% -105.69% -85.52% -62.54% -50.20% -87.86%
EBIT Margin		 -105.06% -102.73% -63.23% -93.23% -176.27% -85.52% -62.53% -50.19% -87.86%
Profit (Net Income) Margin		 -96.26% -96.13% -58.28% -88.59% -162.46% -72.59% -52.14% -41.92% -79.26%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.01% 100.00% 100.00% 100.00% 100.01% 100.00%
Interest Burden Percent		 91.62% 93.58% 92.18% 95.01% 92.17% 84.88% 83.38% 83.51% 90.21%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -435.49% -360.21% -293.15% -1,086.74% -223.90%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -424.73% -358.06% -291.45% -1,085.52% -222.03%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 392.62% 327.28% 265.30% 1,066.16% 199.05%
Return on Equity (ROE)		 0.00% 0.00% 0.00% -81.35% -42.88% -32.93% -27.85% -20.57% -24.86%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -354.29% -222.02%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -46.76% -36.41% -20.22% -16.78% -21.04% -30.15%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -44.43% -33.56% -17.16% -13.99% -17.57% -27.20%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% 271.00% -42.88% -32.93% -27.85% -2.39% -24.86%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% -22.62% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.62 -8.25 -7.68 -9.13 -13 -14 -12 -11 -17
NOPAT Margin		 -51.16% -54.82% -46.00% -44.65% -73.98% -59.86% -43.78% -35.14% -61.50%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% -9.18% -10.76% -2.15% -1.70% -1.22% -1.87%
Return On Investment Capital (ROIC_SIMPLE)		 - - - 3.81% -4.09% -4.53% -3.97% -3.85% -6.15%
Cost of Revenue to Revenue		 44.32% 46.27% 46.64% 42.81% 49.14% 46.20% 44.52% 41.02% 40.50%
SG&A Expenses to Revenue		 27.16% 30.20% 30.56% 23.03% 37.54% 33.91% 29.07% 26.78% 34.81%
R&D to Revenue		 42.36% 42.20% 30.78% 45.08% 43.03% 38.18% 30.07% 31.54% 37.49%
Operating Expenses to Revenue		 128.77% 132.05% 119.07% 120.97% 156.55% 139.32% 118.01% 109.17% 147.35%
Earnings before Interest and Taxes (EBIT)		 -14 -15 -11 -19 -31 -20 -17 -16 -24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -15 -9.95 -19 -30 -19 -16 -15 -23
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 1.20 2.09 2.94 4.29 1.64
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 1.20 2.09 2.94 4.29 1.64
Price to Revenue (P/Rev)		 0.00 0.00 0.00 3.13 5.38 8.10 9.79 12.32 4.04
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 3.62 13.73 22.63 34.45 5.72
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 6.56 1.23 4.56 6.76 9.73 1.91
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.08 0.02 0.02 0.02 0.02 0.02
Long-Term Debt to Equity		 0.00 0.00 0.00 0.08 0.02 0.02 0.02 0.02 0.02
Financial Leverage		 0.00 0.00 0.00 -1.29 -0.92 -0.91 -0.91 -0.98 -0.90
Leverage Ratio		 0.00 0.00 0.00 1.93 1.08 1.09 1.12 1.32 1.10
Compound Leverage Factor		 0.00 0.00 0.00 1.83 0.99 0.93 0.93 1.10 0.99
Debt to Total Capital		 0.00% 0.00% 0.00% 7.01% 1.71% 1.68% 1.90% 1.83% 1.84%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 7.01% 1.71% 1.68% 1.90% 1.83% 1.84%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 393.17% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 0.00% 0.00% -300.17% 98.29% 98.32% 98.10% 98.17% 98.16%
Debt to EBITDA		 0.00 0.00 0.00 -0.10 -0.07 -0.07 -0.07 -0.07 -0.07
Net Debt to EBITDA		 0.00 0.00 0.00 1.74 3.93 3.53 3.17 3.19 3.21
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.10 -0.07 -0.07 -0.07 -0.07 -0.07
Debt to NOPAT		 0.00 0.00 0.00 -0.18 -0.14 -0.12 -0.12 -0.11 -0.09
Net Debt to NOPAT		 0.00 0.00 0.00 3.09 7.61 6.30 5.59 5.17 4.33
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.18 -0.14 -0.12 -0.12 -0.11 -0.09
Altman Z-Score		 0.00 0.00 0.00 -0.20 8.72 12.93 14.22 17.45 7.24
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 433.13% 0.00% 0.00% 0.00% 88.38% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 0.00 0.00 0.00 6.29 15.88 14.68 10.64 8.66 10.69
Quick Ratio		 0.00 0.00 0.00 5.46 14.58 13.40 9.46 7.64 9.28
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 0.00 -37 -40 -38 -61 -30
Operating Cash Flow to CapEx		 -3,411.24% -2,413.61% -500.42% -2,545.28% -5,998.50% -764.14% -680.89% -453.34% -1,730.72%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.50 0.21 0.24 0.27 0.42 0.34
Accounts Receivable Turnover		 0.00 0.00 0.00 7.92 7.71 6.85 7.68 6.89 8.89
Inventory Turnover		 0.00 0.00 0.00 4.01 2.05 2.08 1.98 2.55 2.39
Fixed Asset Turnover		 0.00 0.00 0.00 17.96 12.66 12.07 11.99 14.99 14.07
Accounts Payable Turnover		 0.00 0.00 0.00 14.55 9.31 10.50 9.03 11.39 16.37
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 46.08 47.36 53.31 47.55 53.00 41.07
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 90.92 178.46 175.90 184.57 143.02 152.45
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 25.08 39.19 34.77 40.42 32.04 22.30
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 111.92 186.63 194.44 191.71 163.98 171.22
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 0.00 0.00 0.00 -22 24 26 26 28 37
Invested Capital Turnover		 0.00 0.00 0.00 -2.98 5.89 6.02 6.70 30.93 3.64
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 0.00 24 26 26 50 13
Enterprise Value (EV)		 0.00 0.00 0.00 428 86 356 599 976 211
Market Capitalization		 204 204 204 204 376 632 867 1,235 445
Book Value per Share		 $0.00 $0.00 $0.00 ($38.55) $7.24 $6.96 $6.78 $6.53 $6.11
Tangible Book Value per Share		 $0.00 $0.00 $0.00 ($38.55) $7.24 $6.96 $6.78 $6.53 $6.11
Total Capital		 0.00 0.00 0.00 82 319 307 300 293 276
Total Debt		 0.00 0.00 0.00 5.73 5.45 5.17 5.71 5.37 5.07
Total Long-Term Debt		 0.00 0.00 0.00 5.73 5.45 5.17 5.71 5.37 5.07
Net Debt		 0.00 0.00 0.00 -98 -290 -276 -268 -259 -234
Capital Expenditures (CapEx)		 0.36 0.51 1.92 0.56 0.33 1.78 1.28 1.90 1.38
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 8.20 14 17 16 18 25
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 112 245 267 245 237 225
Net Working Capital (NWC)		 0.00 0.00 0.00 112 245 267 245 237 225
Net Nonoperating Expense (NNE)		 5.83 6.21 2.05 8.98 16 2.96 2.28 2.18 4.91
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -98 -290 -276 -268 -259 -234
Total Depreciation and Amortization (D&A)		 0.56 0.58 0.62 0.53 0.60 0.65 0.68 1.00 1.07
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 12.59% 19.98% 21.62% 18.01% 17.71% 22.84%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 171.63% 351.46% 341.68% 276.21% 236.39% 203.92%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 171.63% 351.46% 341.68% 276.21% 236.39% 203.92%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($2.70) ($0.93) ($0.39) ($0.33) ($0.16) ($0.49)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 6.37M 30.71M 43.39M 43.63M 40.53M 44.44M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.70) ($0.93) ($0.39) ($0.33) ($0.16) ($0.49)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 6.37M 30.71M 43.39M 43.63M 40.53M 44.44M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 43.35M 43.36M 43.47M 44.02M 44.38M 44.56M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.62 -8.25 -7.68 -9.13 -13 -14 -12 -11 -17
Normalized NOPAT Margin		 -51.16% -54.82% -46.00% -44.65% -73.98% -59.86% -43.78% -35.14% -61.50%
Pre Tax Income Margin		 -96.26% -96.13% -58.28% -88.58% -162.46% -72.59% -52.14% -41.92% -79.26%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -7.57% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Beta Bionics (NASDAQ: BBNX) continued to grow revenue in Q1 2026, but the company remains unprofitable and is still burning cash. The latest quarter showed a healthier balance sheet than a year ago, with strong liquidity and a large investment portfolio, but operating losses are still substantial.

  • Revenue rose to $27.6 million in Q1 2026 from $17.6 million in Q1 2025, showing continued top-line growth.
  • Gross profit increased to $16.4 million from $9.0 million a year earlier, indicating better scale.
  • Cash, cash equivalents, and short-term investments totaled about $199.6 million at the end of Q1 2026, giving the company a strong liquidity cushion.
  • Total assets were $304.4 million versus total liabilities of only $33.2 million, so the balance sheet remains conservative.
  • Net cash from investing activities was positive in Q1 2026, helped by $48.0 million of investment maturities/sales, which supported cash preservation.
  • The company generated $2.4 million of interest and investment income in Q1 2026, providing a meaningful offset to operating losses.
  • Operating expenses remain high, with marketing expense of $20.7 million and R&D of $10.4 million in Q1 2026.
  • Shares outstanding have increased sharply over the past year, reflecting prior dilution and a much larger share base than in early 2024.
  • The company reported an operating loss of $24.3 million in Q1 2026 and a net loss of $21.9 million.
  • Cash from operations was negative at ($23.8 million) in Q1 2026, showing the core business is still consuming cash.

Looking at the bigger trend, Beta Bionics has improved revenue materially since 2024, but losses have remained persistent even as sales grew. Quarterly revenue has climbed from $13.0 million in Q1 2024 to $27.6 million in Q1 2026, which is a solid sign of commercialization progress. However, operating expenses have also scaled aggressively, so profitability has not improved enough yet to offset those costs.

The balance sheet is the main bright spot. At $199.6 million in cash and short-term investments, the company appears well positioned to fund operations for now. That said, the business is still using cash each quarter, so investors will likely remain focused on how quickly revenue can keep growing and whether operating losses start narrowing meaningfully.

Bottom line: Beta Bionics looks financially stable in the near term thanks to its cash and investment position, but it is still a loss-making growth company. For retail investors, the key question is whether revenue growth can eventually outrun marketing and R&D spending enough to move the company toward breakeven.

07/01/26 06:16 AM ETAI Generated. May Contain Errors.

Beta Bionics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Beta Bionics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Beta Bionics' net income appears to be on an upward trend, with a most recent value of -$73.20 million in 2025, rising from -$44.10 million in 2023. The previous period was -$54.76 million in 2024. Check out Beta Bionics' forecast to explore projected trends and price targets.

Beta Bionics' total operating income in 2025 was -$71.68 million, based on the following breakdown:
  • Total Gross Profit: $55.54 million
  • Total Operating Expenses: $127.22 million

Over the last 2 years, Beta Bionics' total revenue changed from $12.00 million in 2023 to $100.25 million in 2025, a change of 735.8%.

Beta Bionics' total liabilities were at $41.13 million at the end of 2025, a 44.1% decrease from 2024, and a 20.0% decrease since 2023.

In the past 2 years, Beta Bionics' cash and equivalents has ranged from $26.57 million in 2023 to $31.58 million in 2025, and is currently $31.58 million as of their latest financial filing in 2025.

Over the last 2 years, Beta Bionics' book value per share changed from -38.30 in 2023 to 6.53 in 2025, a change of -117.1%.


Related Companies

Financial statements for NASDAQ:BBNX last updated on 6/25/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel